Background.
Pathological complete response (pCR, ypT0N0) after neoadjuvant therapy is regarded as an exceptionally favorable prognostic factor in locally advanced gastric and esophagogastric junction cancer. The incidence of disease progression in this subgroup and the factors that might predict it remain insufficie...
V. Skoropad, E. Smolenov, V. Grinevich et al.· Siberian journal of oncology· 0 citations
OBJECTIVE: to analyze existing definitions of “textbook outcome” (TO) in colorectal cancer surgery and to justify the need for their standardization.
P
ATIENT
S
AND
METHODS: a systematic review was conducted in accordance with the PRISMA guidelines. PubMed, the Cochrane Library, and eLIBRARY were searche...
V. Lyadov, M. A. Emtsev· Koloproktologia· 0 citations
The frequency and distribution of common, clinically relevant, and rare DPYD variants in a Russian cohort of patients receiving fluoropyrimidine-containing chemotherapy and the observed allele frequencies with European and East Asian reference populations are compared.
D. Fedorinov, V. Lyadov, M. Lyadova et al.· Genes· 0 citations
The combination of atezolizumab with platinum-based chemotherapy and etoposide as a first-line treatment for SCLC demonstrates high efficacy and an acceptable safety profile in real-world clinical settings.
Julia S. Mansurova, M. Lyadova, E. A. Denisova et al.· Journal of Modern Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
